Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 3/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7995890 | 0.91 | ESR2 (0.44) | ESR2NR1H2MAPK1PDK4GPR119 | |
| SCHEMBL951733 | 0.89 | NR1H2 (0.47) | ESR2NR1H2MAPK1PDK4GPR119 | |
| SCHEMBL951850 | 0.85 | ESR2 (0.48) | ESR2NR1H2MAPK1PDK4GPR119 | |
| SCHEMBL3799422 | 0.84 | ESR2 (0.44) | ESR2NR1H2GRM5GRM1ADORA1 | |
| SCHEMBL1751534 | 0.80 | CREBBP (0.42) | ESR2NR1H2MAPK1GPR119GRM5 | |
| SCHEMBL8264160 | 0.80 | USP30 (0.47) | ESR2NR1H2MAPK1PDK4GPR119 | |
| SCHEMBL3693556 | 0.80 | ESR2 (0.44) | ESR2NR1H2MAPK1PDK4GPR119 | |
| SCHEMBL8263481 | 0.79 | MEN1 (0.43) | ESR2NR1H2MAPK1UCHL1GRM5 | |
| SCHEMBL22418001 | 0.78 | ESR2 (0.42) | ESR2NR1H2MAPK1PDK4GPR119 | |
| SCHEMBL3648553 | 0.78 | ESR2 (0.45) | ESR2NR1H2GPR119GRM5GRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580821-B2 | Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety | HOFFMANN-LA ROCHE INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580821-B2 | Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety | HOFFMANN-LA ROCHE INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580821-B2 | Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety | HOFFMANN-LA ROCHE INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130253201-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYL CARBOCYCLIC ACIDS | HOFFMANN-LA ROCHE INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130253201-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYL CARBOCYCLIC ACIDS | HOFFMANN-LA ROCHE INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130253201-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYL CARBOCYCLIC ACIDS | HOFFMANN-LA ROCHE INC. (US) | 2013-09-26 | — | — | US | disclosed |
| EP-2188266-B1 | Novel piperazine amide derivatives | HOFFMANN LA ROCHE (CH) | 2012-10-17 | — | — | EP | disclosed |
| US-8288541-B2 | Piperazine amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-10-16 | — | — | US | disclosed |
| EP-2004605-B1 | PIPERIDINE DERIVATIVES USEFUL AS SEROTONIN TRANSPORTER INHIBITORS AND NEUROKININ-1 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-06-29 | — | — | EP | disclosed |
| EP-2004605-B1 | PIPERIDINE DERIVATIVES USEFUL AS SEROTONIN TRANSPORTER INHIBITORS AND NEUROKININ-1 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-06-29 | — | — | EP | disclosed |
| EP-2004605-A1 | PIPERIDINE DERIVATIVES USEFUL AS SEROTONIN TRANSPORTER INHIBITORS AND NEUROKININ-1 RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007113155-A1 | PROCESS FOR PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC Β-ARYL OR HETEROARYL CARBOXYLIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007113153-A1 | PIPERIDINE DERIVATIVES USEFUL AS SEROTONIN TRANSPORTER INHIBITORS AND NEUROKININ-1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007113153-A1 | PIPERIDINE DERIVATIVES USEFUL AS SEROTONIN TRANSPORTER INHIBITORS AND NEUROKININ-1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-10-11 | — | — | WO | disclosed |
| US-20070232653-A1 | Process for the preparation of enantiomerically enriched cyclic beta-aryl or heteroaryl carbocyclic acids | HOFFMANN-LA ROCHE INC. | 2007-10-04 | — | — | US | disclosed |
| US-20070232653-A1 | Process for the preparation of enantiomerically enriched cyclic beta-aryl or heteroaryl carbocyclic acids | HOFFMANN-LA ROCHE INC. | 2007-10-04 | — | — | US | disclosed |
| US-20070232653-A1 | Process for the preparation of enantiomerically enriched cyclic beta-aryl or heteroaryl carbocyclic acids | HOFFMANN-LA ROCHE INC. | 2007-10-04 | — | — | US | disclosed |
| US-20070232652-A1 | Serotonin transporter (sert) inhibitors for the treatment of depression and anxiety | HOFFMAN-LA ROCHE INC. | 2007-10-04 | — | — | US | disclosed |
| US-20070232652-A1 | Serotonin transporter (sert) inhibitors for the treatment of depression and anxiety | HOFFMAN-LA ROCHE INC. | 2007-10-04 | — | — | US | disclosed |
| US-20070232652-A1 | Serotonin transporter (sert) inhibitors for the treatment of depression and anxiety | HOFFMAN-LA ROCHE INC. | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232652-A1 | Serotonin transporter (sert) inhibitors for the treatment of depression and anxiety | SLC6A4, SLC6A1, SLC1A2 | ESR2 1891/4885NR1H2 858/4885MAPK1 437/4885 |
| US-20130253201-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYL CARBOCYCLIC ACIDS | AHR, CYP8B1, ADRA2C | ESR2 168/4885NR1H2 113/4885MAPK1 2806/4885 |
| US-20070232653-A1 | Process for the preparation of enantiomerically enriched cyclic beta-aryl or heteroaryl carbocyclic acids | AHR, CYP8B1, ADRA2C | ESR2 168/4885NR1H2 113/4885MAPK1 2806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.